ALKS
Price
$28.91
Change
-$0.01 (-0.03%)
Updated
Aug 29, 03:47 PM (EDT)
Capitalization
4.78B
54 days until earnings call
ESPR
Price
$2.21
Change
-$0.00 (-0.00%)
Updated
Aug 29, 03:57 PM (EDT)
Capitalization
445.59M
68 days until earnings call
Interact to see
Advertisement

ALKS vs ESPR

Header iconALKS vs ESPR Comparison
Open Charts ALKS vs ESPRBanner chart's image
Alkermes
Price$28.91
Change-$0.01 (-0.03%)
Volume$500
Capitalization4.78B
Esperion Therapeutics
Price$2.21
Change-$0.00 (-0.00%)
Volume$1.27K
Capitalization445.59M
ALKS vs ESPR Comparison Chart in %
Loading...
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALKS vs. ESPR commentary
Aug 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALKS is a StrongBuy and ESPR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 30, 2025
Stock price -- (ALKS: $28.93 vs. ESPR: $2.21)
Brand notoriety: ALKS and ESPR are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ALKS: 67% vs. ESPR: 79%
Market capitalization -- ALKS: $4.78B vs. ESPR: $445.59M
ALKS [@Pharmaceuticals: Generic] is valued at $4.78B. ESPR’s [@Pharmaceuticals: Generic] market capitalization is $445.59M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.6B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALKS’s FA Score shows that 0 FA rating(s) are green whileESPR’s FA Score has 0 green FA rating(s).

  • ALKS’s FA Score: 0 green, 5 red.
  • ESPR’s FA Score: 0 green, 5 red.
According to our system of comparison, ESPR is a better buy in the long-term than ALKS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALKS’s TA Score shows that 7 TA indicator(s) are bullish while ESPR’s TA Score has 2 bullish TA indicator(s).

  • ALKS’s TA Score: 7 bullish, 3 bearish.
  • ESPR’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, ALKS is a better buy in the short-term than ESPR.

Price Growth

ALKS (@Pharmaceuticals: Generic) experienced а -0.45% price change this week, while ESPR (@Pharmaceuticals: Generic) price change was +3.76% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.25%. For the same industry, the average monthly price growth was +68.20%, and the average quarterly price growth was +81.63%.

Reported Earning Dates

ALKS is expected to report earnings on Oct 22, 2025.

ESPR is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.25% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALKS($4.78B) has a higher market cap than ESPR($446M). ALKS YTD gains are higher at: 0.591 vs. ESPR (0.455). ALKS has higher annual earnings (EBITDA): 450M vs. ESPR (-32.5M). ALKS has more cash in the bank: 1.02B vs. ESPR (86.1M). ALKS has less debt than ESPR: ALKS (72.7M) vs ESPR (302M). ALKS has higher revenues than ESPR: ALKS (1.51B) vs ESPR (268M).
ALKSESPRALKS / ESPR
Capitalization4.78B446M1,071%
EBITDA450M-32.5M-1,385%
Gain YTD0.5910.455130%
P/E Ratio13.98N/A-
Revenue1.51B268M562%
Total Cash1.02B86.1M1,180%
Total Debt72.7M302M24%
FUNDAMENTALS RATINGS
ALKS vs ESPR: Fundamental Ratings
ALKS
ESPR
OUTLOOK RATING
1..100
2022
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
38
Fair valued
PROFIT vs RISK RATING
1..100
40100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5536
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ESPR's Valuation (38) in the Biotechnology industry is somewhat better than the same rating for ALKS (97). This means that ESPR’s stock grew somewhat faster than ALKS’s over the last 12 months.

ALKS's Profit vs Risk Rating (40) in the Biotechnology industry is somewhat better than the same rating for ESPR (100). This means that ALKS’s stock grew somewhat faster than ESPR’s over the last 12 months.

ALKS's SMR Rating (100) in the Biotechnology industry is in the same range as ESPR (100). This means that ALKS’s stock grew similarly to ESPR’s over the last 12 months.

ESPR's Price Growth Rating (36) in the Biotechnology industry is in the same range as ALKS (55). This means that ESPR’s stock grew similarly to ALKS’s over the last 12 months.

ESPR's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ALKS (100). This means that ESPR’s stock grew similarly to ALKS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALKSESPR
RSI
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
N/A
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
63%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 8 days ago
75%
Bullish Trend 8 days ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
62%
Bearish Trend 18 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
59%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CAEIX13.17N/A
N/A
Calvert Global Energy Solutions I
RYCRX33.84N/A
N/A
Rydex Real Estate C
GCSSX27.35N/A
N/A
Goldman Sachs Small Cap Eq Insghts Svc
VZICX31.83N/A
N/A
Vanguard International Core Stock Adm
TEGAX41.73N/A
N/A
Touchstone Mid Cap Growth A

ALKS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALKS has been loosely correlated with AMRX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ALKS jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALKS
1D Price
Change %
ALKS100%
-1.09%
AMRX - ALKS
39%
Loosely correlated
+2.03%
COLL - ALKS
36%
Loosely correlated
-1.13%
PRGO - ALKS
33%
Poorly correlated
-0.54%
PAHC - ALKS
32%
Poorly correlated
+19.44%
PCRX - ALKS
32%
Poorly correlated
+2.76%
More

ESPR and

Correlation & Price change

A.I.dvisor tells us that ESPR and DVAX have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESPR and DVAX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESPR
1D Price
Change %
ESPR100%
+1.38%
DVAX - ESPR
32%
Poorly correlated
+0.10%
AQST - ESPR
32%
Poorly correlated
-0.52%
ALKS - ESPR
30%
Poorly correlated
-1.09%
HROW - ESPR
28%
Poorly correlated
+0.52%
AMRX - ESPR
27%
Poorly correlated
+2.03%
More